Corrupt practices cost healthcare $23 billion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Corrupt practices cost healthcare $23 billion


Pharmaceutical Technology Europe

Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO). In a fact sheet on its website, the WHO explains that corruption occurs throughout all stages of the medicines chain, from R&D to dispensing and promotion, and results in the loss of enormous amounts of public health resources. An estimated 10–25% of public procurement spending, including on pharmaceuticals, is lost to corruption. In developing countries, however, up to 89% leakage of procurement and operational costs has been observed.

"Unethical practices along the chain can take many forms such a falsification of evidence, mismanagement of conflict of interest or bribery," says the fact sheet. Examples include conducting clinical trials without regulatory approval, selecting a non-essential medicine for the essential medicines list and promoting the excessive use of medicine to increase profits.

Although some cases are highlighted by the media and regulatory authorities, many unethical practices go unreported. "This is due to fear of victimization and retaliation towards whistle-blowers, and a lack of incentives to come forward," says the fact sheet. "Some forms of corruption have become institutionalized to the point where people feel powerless to influence change in their countries."

According to the WHO, countries with weak governance within the medicines chain are more susceptible to being exploited by corruption as they lack appropriate medicines regulation, enforcement mechanisms and conflict of interest management. Countries with a higher incidence of corruption also have higher child mortality rates, even after statistically controlling the quality for healthcare provision.

To reduce corruption, the WHO believes that thorough checks are required at each step of the medicines chain. "Good governance, transparency, accountability, promoting institutional integrity and moral leadership are also essential," explains the fact sheet.

www.who.int

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here